We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Curis is a biotechnology company focused on the development and commercialization of innovative cancer therapeutics including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis also collaborates with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, the TIM3/PDL1 antagonist CA-327, and the IRAK4 kinase inhibitor, CA-4948. CA-170 is undergoing Phase 1 testing in patients with advanced solid tumors and lymphomas, and Phase 2 testing in India conducted by Aurigene. CA-4948 is currently in a Phase 1 trial in patients with NHL. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.